Latest Chemotherapy-induced neutropenia Stories
The fight against cancer is not won in a single battle: Long after a cancer has been beaten into remission, it can return.
PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc.
Heart failure is a common, costly, disabling, and potentially deadly condition that affects nearly 10 percent of adults over the age of 65 - and adding cancer to the equation decreases survival rates monumentally.
MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its biosimilar filgrastim product, Nivestim(TM).
LEAMINGTON SPA, United Kingdom, June 10 /PRNewswire-FirstCall/ -- Hospira announced today that the EC has approved Nivestim(TM) (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy(1).
Multicenter trial led by St Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients.
LOS ANGELES, Sept.
Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company's collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics.